Rgenta Therapeutics Secures $46 Million Upfront in Strategic RNA-Targeted Splice Modulator Collaboration with GSK

Today (December 5), Rgenta Therapeutics, Inc.The company announced that it has signed a multi-year, multi-target strategic research collaboration agreement with GlaxoSmithKline (GSK).Aimed at advancing the discovery and development of novel targeted RNA small molecule splicing modulators in multiple disease areas including oncology.。

Dr. Christopher Austin, Senior Vice President of Research Technology at GSK, stated: "We are very excited about Rgenta's differentiated approach to discovering and developing oral small molecule splicing modulators for high-value targets. We are committed to collaborating with leading companies in the industry to further enhance our existing expertise in the field of RNA-targeted therapeutics. At the same time, we look forward to this highly promising innovative therapy benefiting more patients suffering from difficult-to-treat diseases."

Dr. Hua Lin Xi, co-founder and CEO of Rgenta, stated: "We are very pleased to have reached a collaboration with GSK, a global leading biopharmaceutical company. This collaboration further validates the potential of Rgenta’s RNA-targeting small molecule drug discovery platform. Through this partnership, we hope to jointly accelerate the development of this new class of drugs and bring new treatment options to patients."

Dr. Travis Wager, Co-founder, President, and Chief Scientific Officer of Rgenta, added, "We are deeply honored to collaborate with GSK, whose science-driven philosophy and successful track record of leveraging scientific innovation for patient benefit strongly align with our mission. This collaboration further validates the value of our discovery platform, which has successfully advanced our first clinical-stage candidate, RGT-61159—an orally available small molecule designed to specifically modulate the transcription factor MYB."

Rgenta Therapeutics is a clinical-stage biotechnology company,Dedicated to developing a series of targeted RNA oral small molecule drugs for cancer and neurological diseasesOne of Rgenta's main R&D projectsRGT-61159 is an orally administered small molecule designed to specifically modulate the splicing of the transcription factor MYB., which is currently in Phase 1a/b studies, shows potential for the treatment of adenoid cystic carcinoma (ACC), colorectal cancer (CRC) and other solid tumors, as well as acute myeloid leukemia (AML). Rgenta's unique technology platform can identify RNA targets that can be selectively modulated by small molecules, andDesign small molecule glues to modulate the spliceosome, regulating interactions between proteins and RNA.Rgenta focuses on unlocking the therapeutic potential of traditionally undruggable targets through unique approaches and core projects.

Scan the WeChat QR code, add the editor of the Biologics Circle, and those who meet the requirements can join.

Biological Products WeChat Group!